Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: A pilot study

Human Psychopharmacology

Volumn 23, Issue 4, 2008, Pages 327-332

  Yoshimura, Reiji ^a   Kakihara, Shingo ^a   Umene Nakano, Wakako ^a   Sugita, Atsuko ^a   Hori, Hikaru ^a   Ueda, Nobuhisa ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Caffeine; Cigarette smoking; Cotinine; Risperidone; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CAFFEINE; COTININE; RISPERIDONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CORRELATION COEFFICIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SHORT COURSE THERAPY; TREATMENT DURATION;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COFFEE; COTININE; DRINKING; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PREVALENCE; RISPERIDONE; SCHIZOPHRENIA; SMOKING;

EID: 47249121401     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.928     Document Type: Article

References (38)

1. Carillo JA, Benietz J. 2000. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 39: 127-153.
2. Combs DR, Advokat C. 2000. Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr Res 46: 129-137.
3. Corrigall WA, Franklin KBJ, Coen KM, Clarke PB. 1992. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107: 285-289.
4. Dawe S, Gerada C, Russell MAH, Gray JA. 1995. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology 117: 110-115.
5. De Freitas B, Schwartz G. 1979. Effects of caffeine in chronic psychiatric patients. Am J Psychiatry 136: 1337-1338.
6. De Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. 2005. Does clozapine decrease smoking? Prog Neuropsychopharmacol Biol Psychiatry 29: 757-762.
7. De Leon J, Tracy J, McCann E, McGrory A, Diaz FJ. 2002. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 56: 55-65.
8. Donovan JL, DeVane CL. 2001. A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology. Psychopharmacol Bull 35: 30-48.
9. Evins AE, Cather C, Deckersbach T, et al. 2005. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 25: 218-225.
10. Evins AE, Cather C, Culhane MA, et al. 2007. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 27: 380-386.
11. Fatemi SH, Stary JM, Hatsukami DK. 2005. A double-blind controlled cross over trial of bupuropion in smoking reduction in schizophrenia. Schizophr Res 76:Evins AE, Cather C, Deckersbach T. A double-blind placebo-controlled trial of bupuropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 25: 218-225.
12. Ferre S, Fuxe K, Von Euler G. 1992. Adenosine-dopamine interactions in the brain. Neuroscience 51: 501-512.
13. George TP, Sernyak MJ, Ziedonis DM, Woods SW. 1995. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 56: 344-346.
14. George TP, Ziedonis DM, Feingold A. 2000. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 157: 1835-1842.
15. Goff DC, Henderson DC, Amico E. 1992. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149: 1189-1194.
16. Hurt RD, Sachs DP, Glover ED. 1997. A comparison of sustained-release bupuropion and placebo for smoking cessation. N Engl J Med 337: 1195-1202.
17. Kakihara S, Yoshimura R, Shinkai K, et al. 2005. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2 D6. Int Clin Psychopharmacol 20: 71-78.
18. Kelly C, McCreadie RG. 1999. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 156: 1751-1757.
19. Kirubakaran V. 1986. Hyponatremic coma and elevated serum creatine phosphokinase following excessive caffeine intake. Psychiatr J Univ Ott 11: 105-106.
20. Koczapski A, Paredes J, Kogan C, Ledwidge B, Higenbottam J. 1989. Effects of caffeine on behavior of schizophrenic inpatients. Schizophr Bull 15: 339-344.
21. Kruger A. 1996. Chronic psychiatric patients' use of caffeine: pharmacological effects and mechanisms. Psychol Rep 78: 915-923.
22. Levy DT, Nikolayev L, Mumford E. 2005. Recent trends in smoking and the role of public policies: results for the SimSmoke tobacco control policy simulation model. Addiction 100: 1526-1536.
23. Lucas PB, Pickar D, Kelsoe J. 1990. Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28: 35-40.
24. Maurice E, Trosclair A, Merritt R, et al. 2005. Cigarette smoking among adults - United States, 2004. MMWR 54: 1121-1124.
25. Mayo KM, Falkowski W, Jones CAH. 1993. Caffeine: use and effects in long-stay psychiatric patients. Br J Psychiatry 162: 543-545.
26. McCreadie RG. on behalf of the Scottisch Schizophrenia Lifestyle Group. 2003. Diet, smoking and cardiovascular risk in people with schizophrenia. Br J Psychiatry 183: 534-539.
27. McEvoy JP, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J. 1995a. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 37: 550-552.
28. McEvoy J, Freudenreich O, Levin E, Rose J. 1995b. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 119: 124-126.
29. McEvoy Freudenreich O, Wilson WH. 1999. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 46: 125-129.
30. Menza MA, Grossman N, Van Horn M, Cody R, Forman N. 1991. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 30: 109-115.
31. Miyamoto K, Yoshimura R, Ueda N, et al. 2007. Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients. Hum Psychopharmacology 22: 483-490.
32. Moghaddam B, Bunney BS. 1990. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755-1760.
33. Procyshyn RM, Ihsan N, Thompson D. 2001. A comparison of smoking behaviors between patients treated with clozapine and depot neuroleptics. Int Clin Psychopharmacol 16: 291-294.
34. Rogers PJ, Heatherley SV, Hayward RC, Seers HE, Hill J, Kane M. 2005. Effects of caffeine and caffeine withdrawal on mood and cognitive performance degraded by sleep restriction. Psychopharmacology 179: 742-752.
35. Strassnig M, Brar JS, Ganguli R. 2006. Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophr Res86: 269-275.
36. Swanson JA, Lee JW, Hopp JW. 1994. Caffeine and nicotine: a review of their joint use and possible interactive effects in tobacco withdrawal. Affect Behav 19: 229-256.
37. Wall MA, Johnson J, Jacob P, Benowitz NL. 1988. Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers, Am J Public Health 78: 699-701.
38. Ziedonis DM, George TP. 1997. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 23: 247-254.